The selection of Ziftomenib for a significant clinical trial like PedAL indicates a recognition of the drug's potential in treating pediatric acute leukemia. This news could be seen as a validation of Kura Oncology's research and development efforts, which may increase investor optimism about the company's future prospects. The positive sentiment could drive the stock price up in the short term, as investors anticipate potential success in the trial and future regulatory approvals.